Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMayxay, Mayfongen_US
dc.contributor.authorKhanthavong, Maniphoneen_US
dc.contributor.authorCox, Lornaen_US
dc.contributor.authorSichanthongthip, Odaien_US
dc.contributor.authorMallika Imwongen_US
dc.contributor.authorมัลลิกา อิ่มวงศ์en_US
dc.contributor.authorPongvongsa, Tiengkhamen_US
dc.contributor.authorHongvanthong, Bouasyen_US
dc.contributor.authorPhompida, Samlaneen_US
dc.contributor.authorVanisaveth, Viengxayen_US
dc.contributor.authorWhite, Nicholas Jen_US
dc.contributor.authorNewton, Paul Nen_US
dc.contributor.otherMahidol University. Faculty of Tropical Medicine. Department of Molecular Tropical Medicine and Genetics.en_US
dc.identifier.citationMayxay M, Khanthavong M, Cox L, Sichanthongthip O, Imwong M, Pongvongsa T, et al. Thiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laos. Malar J. 2014 Jul 15;13:275.en_US
dc.identifier.issn1475-2875 (electronic)-
dc.description.abstractBackground: In a recent study one third of Lao patients presenting with uncomplicated Plasmodium falciparum malaria had biochemical evidence of thiamin deficiency, which was associated with a higher incidence of adverse events. Thiamin supplementation might, therefore, reduce adverse events in this population. Methods: An exploratory, double-blind, parallel group, placebo-controlled, superiority trial of thiamin supplementation in patients of all ages with uncomplicated and severe falciparum malaria was conducted in Xepon District, Savannakhet Province, southern Laos. Patients were randomly assigned to either oral thiamin 10 mg/day for 7 days immediately after standard anti-malarial treatment then 5 mg daily until day 42, or identical oral placebo. Results: After interim analyses when 630 patients (314 in thiamin and 316 in placebo groups) had been recruited, the trial was discontinued on the grounds of futility. On admission biochemical thiamin deficiency (alpha ≥ 25%) was present in 27% of patients and 9% had severe deficiency (alpha > 31%). After 42 days of treatment, the frequency of thiamin deficiency was lower in the thiamin (2%, 1% severe) compared to the placebo (11%, 3% severe) groups (p < 0.001 and p = 0.05), respectively. Except for diarrhoea, 7% in the placebo compared to 3% in the thiamin group (p = 0.04), and dizziness on day 1 (33% vs 25%, p = 0.045), all adverse events were not significantly different between the groups (p > 0.05). Clinical, haematological, and parasitological responses to treatment did not differ significantly between the two groups. Conclusion: Thiamin supplementation reduced biochemical thiamin deficiency among Lao malaria patients following anti-malarial drug treatment, but it did not reduce the frequency of adverse events after anti-malarial therapy or have any detected clinical or parasitological impact.en_US
dc.rightsMahidol Universityen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectOpen Access articleen_US
dc.titleThiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laosen_US
dc.typeResearch Articleen_US
dc.rights.holderBioMed Centralen_US
dc.contributor.correspondenceMayxay, Mayfongen_US
Appears in Collections:TM-Article

Files in This Item:
File Description SizeFormat 
tm-ar-mallika-2014.pdf658.48 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.